Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We investigated changes in circulating T helper type 17 (Th17) cells following anti-tumour necrosis factor (TNF) in rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients. Peripheral blood mononuclear cells (PBMC) were isolated from 25 RA, 15 AS and eight PsA patients at baseline 4 and 12 weeks after treatment, and Th17 cell frequencies were analysed using interleukin (IL)-17 enzyme-linked immunospot (ELISPOT) and flow cytometry. A significant increase in IL-17-producing cells was observed by ELISPOT in RA and AS patients at 12 weeks. Flow cytometry confirmed significant increases in CD4(+) IL-17(+) cells at 12 weeks in RA and AS and 4 weeks in PsA patients. Anti-TNF treatment increases circulating Th17 cells in three different diseases.

Original publication




Journal article


Clin exp immunol

Publication Date





401 - 406


T cells, ankylosing spondylitis, anti-TNF, psoriatic arthritis, rheumatoid arthritis, Adalimumab, Adult, Aged, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Arthritis, Psoriatic, Arthritis, Rheumatoid, Enzyme-Linked Immunosorbent Assay, Etanercept, Female, Flow Cytometry, Humans, Immunoglobulin G, Interleukin-17, Male, Middle Aged, Prospective Studies, Receptors, Tumor Necrosis Factor, Spondylitis, Ankylosing, Th17 Cells, Time Factors, Treatment Outcome, Tumor Necrosis Factor-alpha